お電話でもお問い合わせください
03-5860-2441
Report thumbnail
商品コード LP0912911485Y4I
出版日 2024/3/4
LP Information
英文124 ページグローバル

肛門がんと大腸がんのグローバル市場成長展望、2024年〜2030年

Global Anal and Colorectal Cancer Market Growth (Status and Outlook) 2024-2030


Report thumbnail
商品コード LP0912911485Y4I◆2025年3月版も出版されている時期ですので、お問い合わせ後すぐに確認いたします。
出版日 2024/3/4
LP Information
英文 124 ページグローバル

肛門がんと大腸がんのグローバル市場成長展望、2024年〜2030年

Global Anal and Colorectal Cancer Market Growth (Status and Outlook) 2024-2030



全体要約

肛門がんおよび大腸がん市場について調査・分析を行った市場レポート。
2023年の肛門がんおよび大腸がん市場の規模は、数百万米ドルと評価されています。2030年までに市場は再調整され、成長率はCAGRで%と予測されています。市場の成長には、製品の差別化、コスト削減、サプライチェーンの最適化が重要です。市場プレーヤーは、研究開発への投資や戦略的パートナーシップの構築が求められています。

肛門がんおよび大腸がん市場は、手術、放射線療法、化学療法、標的療法、免疫療法などのタイプに分かれています。市場は、アメリカ、アジア太平洋、ヨーロッパ、中東・アフリカの地域に分かれ、各地域での成長が期待されています。政府の政策や環境への影響も市場に影響を与える要因として分析されています。

関連する質問

Abbott Diagnostics, Advaxis, Abbott, Amgen, Atara Biotherapeutics, Bayer, Metabiomics, Beckman Coulter, BeiGene, Boehringer Ingelheim, Clinical Genomics, EDP Biotech, Eli Lilly, Epigenomics, Exact Sciences, Genomictree, Immunovaccine, ISA Pharmaceuticals, Merck

製品の差別化, コスト削減, サプライチェーンの最適化


概要

私たちのLPI (LP Information)最新調査によると、2023年の世界の肛門および大腸癌市場規模は、XX米ドルと評価されています。下流市場の需要の増加に伴い、肛門および大腸癌は2030年までに再調整された規模で、レビュー期間中にXX%のCAGRで成長すると予測されています。
この調査報告書は、世界の肛門および大腸癌市場の成長可能性を強調しています。肛門および大腸癌は、今後の市場で安定した成長を示すと予想されています。しかし、製品の差別化、コスト削減、サプライチェーンの最適化は、肛門および大腸癌の広範な採用にとって重要な課題であり続けます。市場のプレーヤーは、研究開発に投資し、戦略的なパートナーシップを構築し、進化する消費者の好みに合わせて提供を調整する必要があります。肛門および大腸癌市場がもたらす巨大な機会を活用するために。
主要な特徴:
アナルおよび大腸癌市場に関する報告書は、さまざまな側面を反映し、業界に対する貴重な洞察を提供します。
市場規模と成長:本調査報告書は、肛門および大腸癌市場の現在の規模と成長についての概要を提供します。歴史的データ、タイプ別の市場セグメンテーション(例:手術、放射線治療)、地域別の内訳が含まれる場合があります。
市場の推進要因と課題:レポートは、政府の規制、環境問題、技術の進展、消費者の嗜好の変化など、肛門および大腸がん市場の成長を促進する要因を特定し分析できます。また、インフラの制約、充電への不安、高い初期コストなど、業界が直面する課題も明らかにすることができます。
競争環境:この研究報告書では、肛門および大腸癌市場における競争環境の分析が提供されています。主要なプレーヤーのプロフィール、彼らの市場シェア、戦略、および製品の提供が含まれています。また、報告書は新興プレーヤーとその市場への潜在的な影響を強調することもできます。
技術の進展:研究報告は、肛門および大腸癌産業における最新の技術の進展を掘り下げることができます。これには、肛門および大腸癌技術の進歩、肛門および大腸癌の新規参入、肛門および大腸癌の新規投資、及び肛門および大腸癌の未来を形作るその他の革新が含まれます。
下流の市場志向:この報告書は、アナルおよび大腸癌市場における顧客の市場行動や採用動向を明らかにすることができます。顧客の購買決定に影響を与える要因や、アナルおよび大腸癌製品に対する好みが含まれています。
政府の政策とインセンティブ:この研究報告書では、肛門および大腸癌市場に対する政府の政策とインセンティブの影響を分析しています。これには、規制の枠組み、補助金、税制優遇、および肛門および大腸癌市場の促進を目的としたその他の措置の評価が含まれる場合があります。また、この報告書では、これらの政策が市場成長を促進する上での効果を評価しています。
環境影響と持続可能性:この研究報告書は、肛門および大腸癌市場の環境影響と持続可能性の側面を評価しています。
市場予測と将来の展望:実施された分析に基づいて、研究報告書は肛門および大腸癌業界の市場予測と展望を提供します。これには、市場規模、成長率、地域のトレンド、技術の進展や政策の動向に関する予測が含まれます。
推奨事項と機会:報告書は、業界のステークホルダー、政策立案者、および投資家への推奨で締めくくられています。新たなトレンドを活用し、課題を克服し、肛門および大腸癌市場の成長と発展に貢献するための市場プレーヤーの潜在的な機会を強調しています。
市場セグメンテーション:
アナルおよび大腸癌市場は、タイプ別および用途別に分かれています。2019年から2030年の期間において、セグメント間の成長が消費価値の正確な計算と予測を提供します。
タイプ別セグメンテーション
手術
放射線療法
大腸癌化学療法
標的療法
免疫療法
アプリケーション別のセグメンテーション
病院
外来手術センター
がん研究センター
この報告書では、市場を地域ごとに分割しています。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下のプロフィールに記載されている企業は、主要な専門家から得られた意見と、企業のカバレッジ、製品ポートフォリオ、市場浸透度を分析して選定されました。
アボット・ダイアグノスティクス
アドバイグス
アボット
アムジェン
アタラ・バイオセラピューティクス
バイエル
メタバイオミクス
ベックマン・コールター
ベイジーン
バイエルン・インゲルハイム
臨床ゲノム学
EDPバイオテクノロジー
エリ・リリー
エピゲノミクス
エグザクトサイエンシズ
ジェノミクリー
免疫ワクチン
ISAファーマシューティカルズ
メルク

※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。

目次

  • 1 調査範囲

    • 1.1 市場イントロダクション
    • 1.2 対象年
    • 1.3 調査目的
    • 1.4 市場調査手法
    • 1.5 調査プロセスとデータソース
    • 1.6 経済指標
    • 1.7 通貨
    • 1.8 市場予測における留意事項
  • 2 エグゼクティブサマリー

    • 2.1 世界市場概要
      • 2.1.1 グローバルの肛門がんおよび大腸がん市場規模、(2019年~2030年)
      • 2.1.2 肛門がんおよび大腸がん市場規模、CAGR(地域別)(2019年 vs 2023年 vs 2030年)
    • 2.2 肛門がんおよび大腸がんセグメント、タイプ別
      • 2.2.1 手術
      • 2.2.2 放射線治療
      • 2.2.3 大腸がん化学療法
      • 2.2.4 標的療法
      • 2.2.5 免疫療法
    • 2.3 肛門がんおよび大腸がん市場規模:タイプ別
      • 2.3.1 肛門がんおよび大腸がん市場規模、CAGR(タイプ別)(2019年 vs 2023年 vs 2030年)
      • 2.3.2 グローバルの肛門がんおよび大腸がん市場規模、市場シェア(タイプ別)(2019年~2024年)
    • 2.4 肛門がんおよび大腸がんセグメント、用途別
      • 2.4.1 病院
      • 2.4.2 外来手術センター
      • 2.4.3 がん研究センター
    • 2.5 肛門がんおよび大腸がん市場規模:用途別
      • 2.5.1 肛門がんおよび大腸がん市場規模、CAGR(用途別)(2019年 vs 2023年 vs 2030年)
      • 2.5.2 グローバルの肛門がんおよび大腸がん市場規模、市場シェア(用途別)(2019年~2024年)
  • 3 肛門がんおよび大腸がん市場規模:プレイヤー別

    • 3.1 肛門がんおよび大腸がん市場規模、市場シェア(プレイヤー別)
      • 3.1.1 グローバルにおける肛門がんおよび大腸がん市場の収益規模、プレイヤー別(2019年~2024年)
      • 3.1.2 グローバルにおける肛門がんおよび大腸がん市場の収益シェア、プレイヤー別(2019年~2024年)
    • 3.2 グローバルの肛門がんおよび大腸がん市場キープレイヤー拠点および提供製品
    • 3.3 市場集中度分析
      • 3.3.1 競合情勢分析
      • 3.3.2 集中度レシオ(CR3、CR5、CR10)(2022年~2024年)
    • 3.4 新製品・潜在的参入
    • 3.5 M&A、拡大
  • 4 肛門がんおよび大腸がん、地域別

    • 4.1 肛門がんおよび大腸がん市場規模(地域別)(2019年~2024年)
    • 4.2 アメリカズにおける肛門がんおよび大腸がん市場規模成長(2019年〜2024年)
    • 4.3 APACにおける肛門がんおよび大腸がん市場規模成長(2019年〜2024年)
    • 4.4 ヨーロッパにおける肛門がんおよび大腸がん市場規模成長(2019年〜2024年)
    • 4.5 中東・アフリカにおける肛門がんおよび大腸がん市場規模成長(2019年〜2024年)
  • 5 アメリカズ

    • 5.1 アメリカズにおける肛門がんおよび大腸がん市場規模、国別(2019年〜2024年)
    • 5.2 アメリカズにおける肛門がんおよび大腸がん市場規模、タイプ別(2019年〜2024年)
    • 5.3 アメリカズにおける肛門がんおよび大腸がん市場規模、用途別(2019年〜2024年)
    • 5.4 米国
    • 5.5 カナダ
    • 5.6 メキシコ
    • 5.7 ブラジル
  • 6 APAC

    • 6.1 APACにおける肛門がんおよび大腸がん市場規模、地域別(2019年〜2024年)
    • 6.2 APACにおける肛門がんおよび大腸がん市場規模、タイプ別(2019年〜2024年)
    • 6.3 APACにおける肛門がんおよび大腸がん市場規模、用途別(2019年〜2024年)
    • 6.4 中国
    • 6.5 日本
    • 6.6 韓国
    • 6.7 東南アジア
    • 6.8 インド
    • 6.9 オーストラリア
  • 7 ヨーロッパ

    • 7.1 ヨーロッパの肛門がんおよび大腸がん 国別(2019年~2024年)
    • 7.2 ヨーロッパにおける肛門がんおよび大腸がん市場規模、タイプ別(2019年〜2024年)
    • 7.3 ヨーロッパにおける肛門がんおよび大腸がん市場規模、用途別(2019年〜2024年)
    • 7.4 ドイツ
    • 7.5 フランス
    • 7.6 英国
    • 7.7 イタリア
    • 7.8 ロシア
  • 8 中東・アフリカ

    • 8.1 中東・アフリカの肛門がんおよび大腸がん 地域別(2019年~2024年)
    • 8.2 中東・アフリカにおける肛門がんおよび大腸がん市場規模、タイプ別(2019年〜2024年)
    • 8.3 中東・アフリカにおける肛門がんおよび大腸がん市場規模、用途別(2019年〜2024年)
    • 8.4 エジプト
    • 8.5 南アフリカ
    • 8.6 イスラエル
    • 8.7 トルコ
    • 8.8 GCC地域
  • 9 市場ドライバー・課題・トレンド

    • 9.1 市場ドライバー・成長機会
    • 9.2 市場課題・リスク
    • 9.3 業界トレンド
  • 10 グローバルの肛門がんおよび大腸がん市場、市場予測

    • 10.1 グローバルの肛門がんおよび大腸がん、市場予測(地域別)(2025年~2030年)
      • 10.1.1 グローバルの肛門がんおよび大腸がん、市場予測(地域別)(2025年~2030年)
      • 10.1.2 アメリカズの肛門がんおよび大腸がん、市場予測
      • 10.1.3 APACの肛門がんおよび大腸がん、市場予測
      • 10.1.4 ヨーロッパの肛門がんおよび大腸がん、市場予測
      • 10.1.5 中東・アフリカの肛門がんおよび大腸がん、市場予測
    • 10.2 アメリカズの肛門がんおよび大腸がん、市場予測(国別)(2025年~2030年)
    • 10.3 APACの肛門がんおよび大腸がん、市場予測(地域別)(2025年~2030年)
    • 10.4 ヨーロッパの肛門がんおよび大腸がん、市場予測(国別)(2025年~2030年)
    • 10.5 中東・アフリカの肛門がんおよび大腸がん、市場予測(地域別)(2025年~2030年)
    • 10.6 グローバルの肛門がんおよび大腸がん、市場予測(タイプ別)(2025年~2030年)
    • 10.7 グローバルの肛門がんおよび大腸がん、市場予測(用途別)(2025年~2030年)
  • 11 キープレイヤー分析

    • 11.1 Abbott Diagnostics
      • 11.1.1 Abbott Diagnostics:企業情報
      • 11.1.2 Abbott Diagnostics:肛門がんおよび大腸がん分野の提供製品
      • 11.1.3 Abbott Diagnostics:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.1.4 Abbott Diagnostics:主要事業概要
      • 11.1.5 Abbott Diagnostics:直近の展開
    • 11.2 Advaxis
      • 11.2.1 Advaxis:企業情報
      • 11.2.2 Advaxis:肛門がんおよび大腸がん分野の提供製品
      • 11.2.3 Advaxis:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.2.4 Advaxis:主要事業概要
      • 11.2.5 Advaxis:直近の展開
    • 11.3 Abbott
      • 11.3.1 Abbott:企業情報
      • 11.3.2 Abbott:肛門がんおよび大腸がん分野の提供製品
      • 11.3.3 Abbott:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.3.4 Abbott:主要事業概要
      • 11.3.5 Abbott:直近の展開
    • 11.4 Amgen
      • 11.4.1 Amgen:企業情報
      • 11.4.2 Amgen:肛門がんおよび大腸がん分野の提供製品
      • 11.4.3 Amgen:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.4.4 Amgen:主要事業概要
      • 11.4.5 Amgen:直近の展開
    • 11.5 Atara Biotherapeutics
      • 11.5.1 Atara Biotherapeutics:企業情報
      • 11.5.2 Atara Biotherapeutics:肛門がんおよび大腸がん分野の提供製品
      • 11.5.3 Atara Biotherapeutics:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.5.4 Atara Biotherapeutics:主要事業概要
      • 11.5.5 Atara Biotherapeutics:直近の展開
    • 11.6 Bayer
      • 11.6.1 Bayer:企業情報
      • 11.6.2 Bayer:肛門がんおよび大腸がん分野の提供製品
      • 11.6.3 Bayer:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.6.4 Bayer:主要事業概要
      • 11.6.5 Bayer:直近の展開
    • 11.7 Metabiomics
      • 11.7.1 Metabiomics:企業情報
      • 11.7.2 Metabiomics:肛門がんおよび大腸がん分野の提供製品
      • 11.7.3 Metabiomics:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.7.4 Metabiomics:主要事業概要
      • 11.7.5 Metabiomics:直近の展開
    • 11.8 Beckman Coulter
      • 11.8.1 Beckman Coulter:企業情報
      • 11.8.2 Beckman Coulter:肛門がんおよび大腸がん分野の提供製品
      • 11.8.3 Beckman Coulter:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.8.4 Beckman Coulter:主要事業概要
      • 11.8.5 Beckman Coulter:直近の展開
    • 11.9 BeiGene
      • 11.9.1 BeiGene:企業情報
      • 11.9.2 BeiGene:肛門がんおよび大腸がん分野の提供製品
      • 11.9.3 BeiGene:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.9.4 BeiGene:主要事業概要
      • 11.9.5 BeiGene:直近の展開
    • 11.10 Boehringer Ingelheim
      • 11.10.1 Boehringer Ingelheim:企業情報
      • 11.10.2 Boehringer Ingelheim:肛門がんおよび大腸がん分野の提供製品
      • 11.10.3 Boehringer Ingelheim:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.10.4 Boehringer Ingelheim:主要事業概要
      • 11.10.5 Boehringer Ingelheim:直近の展開
    • 11.11 Clinical Genomics
      • 11.11.1 Clinical Genomics:企業情報
      • 11.11.2 Clinical Genomics:肛門がんおよび大腸がん分野の提供製品
      • 11.11.3 Clinical Genomics:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.11.4 Clinical Genomics:主要事業概要
      • 11.11.5 Clinical Genomics:直近の展開
    • 11.12 EDP Biotech
      • 11.12.1 EDP Biotech:企業情報
      • 11.12.2 EDP Biotech:肛門がんおよび大腸がん分野の提供製品
      • 11.12.3 EDP Biotech:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.12.4 EDP Biotech:主要事業概要
      • 11.12.5 EDP Biotech:直近の展開
    • 11.13 Eli Lilly
      • 11.13.1 Eli Lilly:企業情報
      • 11.13.2 Eli Lilly:肛門がんおよび大腸がん分野の提供製品
      • 11.13.3 Eli Lilly:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.13.4 Eli Lilly:主要事業概要
      • 11.13.5 Eli Lilly:直近の展開
    • 11.14 Epigenomics
      • 11.14.1 Epigenomics:企業情報
      • 11.14.2 Epigenomics:肛門がんおよび大腸がん分野の提供製品
      • 11.14.3 Epigenomics:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.14.4 Epigenomics:主要事業概要
      • 11.14.5 Epigenomics:直近の展開
    • 11.15 Exact Sciences
      • 11.15.1 Exact Sciences:企業情報
      • 11.15.2 Exact Sciences:肛門がんおよび大腸がん分野の提供製品
      • 11.15.3 Exact Sciences:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.15.4 Exact Sciences:主要事業概要
      • 11.15.5 Exact Sciences:直近の展開
    • 11.16 Genomictree
      • 11.16.1 Genomictree:企業情報
      • 11.16.2 Genomictree:肛門がんおよび大腸がん分野の提供製品
      • 11.16.3 Genomictree:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.16.4 Genomictree:主要事業概要
      • 11.16.5 Genomictree:直近の展開
    • 11.17 Immunovaccine
      • 11.17.1 Immunovaccine:企業情報
      • 11.17.2 Immunovaccine:肛門がんおよび大腸がん分野の提供製品
      • 11.17.3 Immunovaccine:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.17.4 Immunovaccine:主要事業概要
      • 11.17.5 Immunovaccine:直近の展開
    • 11.18 ISA Pharmaceuticals
      • 11.18.1 ISA Pharmaceuticals:企業情報
      • 11.18.2 ISA Pharmaceuticals:肛門がんおよび大腸がん分野の提供製品
      • 11.18.3 ISA Pharmaceuticals:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.18.4 ISA Pharmaceuticals:主要事業概要
      • 11.18.5 ISA Pharmaceuticals:直近の展開
    • 11.19 Merck
      • 11.19.1 Merck:企業情報
      • 11.19.2 Merck:肛門がんおよび大腸がん分野の提供製品
      • 11.19.3 Merck:肛門がんおよび大腸がん収益・グロスマージンおよび市場シェア(2019年~2024年)
      • 11.19.4 Merck:主要事業概要
      • 11.19.5 Merck:直近の展開
  • 12 調査の結果・結論

※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”


Description

According to our LPI (LP Information) latest study, the global Anal and Colorectal Cancer market size was valued at US$ million in 2023. With growing demand in downstream market, the Anal and Colorectal Cancer is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Anal and Colorectal Cancer market. Anal and Colorectal Cancer are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Anal and Colorectal Cancer. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Anal and Colorectal Cancer market.
Key Features:
The report on Anal and Colorectal Cancer market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Anal and Colorectal Cancer market. It may include historical data, market segmentation by Type (e.g., Surgery, Radiation therapy), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Anal and Colorectal Cancer market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Anal and Colorectal Cancer market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Anal and Colorectal Cancer industry. This include advancements in Anal and Colorectal Cancer technology, Anal and Colorectal Cancer new entrants, Anal and Colorectal Cancer new investment, and other innovations that are shaping the future of Anal and Colorectal Cancer.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Anal and Colorectal Cancer market. It includes factors influencing customer ' purchasing decisions, preferences for Anal and Colorectal Cancer product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Anal and Colorectal Cancer market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Anal and Colorectal Cancer market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Anal and Colorectal Cancer market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Anal and Colorectal Cancer industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Anal and Colorectal Cancer market.
Market Segmentation:
Anal and Colorectal Cancer market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Surgery
Radiation therapy
Colorectal cancer chemotherapy
Targeted therapy
Immunotherapy
Segmentation by application
Hospitals
Ambulatory surgery centers
Cancer research centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Diagnostics
Advaxis
Abbott
Amgen
Atara Biotherapeutics
Bayer
Metabiomics
Beckman Coulter
BeiGene
Boehringer Ingelheim
Clinical Genomics
EDP Biotech
Eli Lilly
Epigenomics
Exact Sciences
Genomictree
Immunovaccine
ISA Pharmaceuticals
Merck

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Anal and Colorectal Cancer Market Size 2019-2030
      • 2.1.2 Anal and Colorectal Cancer Market Size CAGR by Region 2019 VS 2023 VS 2030
    • 2.2 Anal and Colorectal Cancer Segment by Type
      • 2.2.1 Surgery
      • 2.2.2 Radiation therapy
      • 2.2.3 Colorectal cancer chemotherapy
      • 2.2.4 Targeted therapy
      • 2.2.5 Immunotherapy
    • 2.3 Anal and Colorectal Cancer Market Size by Type
      • 2.3.1 Anal and Colorectal Cancer Market Size CAGR by Type (2019 VS 2023 VS 2030)
      • 2.3.2 Global Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024)
    • 2.4 Anal and Colorectal Cancer Segment by Application
      • 2.4.1 Hospitals
      • 2.4.2 Ambulatory surgery centers
      • 2.4.3 Cancer research centers
    • 2.5 Anal and Colorectal Cancer Market Size by Application
      • 2.5.1 Anal and Colorectal Cancer Market Size CAGR by Application (2019 VS 2023 VS 2030)
      • 2.5.2 Global Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024)
  • 3 Anal and Colorectal Cancer Market Size by Player

    • 3.1 Anal and Colorectal Cancer Market Size Market Share by Players
      • 3.1.1 Global Anal and Colorectal Cancer Revenue by Players (2019-2024)
      • 3.1.2 Global Anal and Colorectal Cancer Revenue Market Share by Players (2019-2024)
    • 3.2 Global Anal and Colorectal Cancer Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Anal and Colorectal Cancer by Regions

    • 4.1 Anal and Colorectal Cancer Market Size by Regions (2019-2024)
    • 4.2 Americas Anal and Colorectal Cancer Market Size Growth (2019-2024)
    • 4.3 APAC Anal and Colorectal Cancer Market Size Growth (2019-2024)
    • 4.4 Europe Anal and Colorectal Cancer Market Size Growth (2019-2024)
    • 4.5 Middle East & Africa Anal and Colorectal Cancer Market Size Growth (2019-2024)
  • 5 Americas

    • 5.1 Americas Anal and Colorectal Cancer Market Size by Country (2019-2024)
    • 5.2 Americas Anal and Colorectal Cancer Market Size by Type (2019-2024)
    • 5.3 Americas Anal and Colorectal Cancer Market Size by Application (2019-2024)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Anal and Colorectal Cancer Market Size by Region (2019-2024)
    • 6.2 APAC Anal and Colorectal Cancer Market Size by Type (2019-2024)
    • 6.3 APAC Anal and Colorectal Cancer Market Size by Application (2019-2024)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Anal and Colorectal Cancer by Country (2019-2024)
    • 7.2 Europe Anal and Colorectal Cancer Market Size by Type (2019-2024)
    • 7.3 Europe Anal and Colorectal Cancer Market Size by Application (2019-2024)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Anal and Colorectal Cancer by Region (2019-2024)
    • 8.2 Middle East & Africa Anal and Colorectal Cancer Market Size by Type (2019-2024)
    • 8.3 Middle East & Africa Anal and Colorectal Cancer Market Size by Application (2019-2024)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Anal and Colorectal Cancer Market Forecast

    • 10.1 Global Anal and Colorectal Cancer Forecast by Regions (2025-2030)
      • 10.1.1 Global Anal and Colorectal Cancer Forecast by Regions (2025-2030)
      • 10.1.2 Americas Anal and Colorectal Cancer Forecast
      • 10.1.3 APAC Anal and Colorectal Cancer Forecast
      • 10.1.4 Europe Anal and Colorectal Cancer Forecast
      • 10.1.5 Middle East & Africa Anal and Colorectal Cancer Forecast
    • 10.2 Americas Anal and Colorectal Cancer Forecast by Country (2025-2030)
      • 10.2.1 United States Anal and Colorectal Cancer Market Forecast
      • 10.2.2 Canada Anal and Colorectal Cancer Market Forecast
      • 10.2.3 Mexico Anal and Colorectal Cancer Market Forecast
      • 10.2.4 Brazil Anal and Colorectal Cancer Market Forecast
    • 10.3 APAC Anal and Colorectal Cancer Forecast by Region (2025-2030)
      • 10.3.1 China Anal and Colorectal Cancer Market Forecast
      • 10.3.2 Japan Anal and Colorectal Cancer Market Forecast
      • 10.3.3 Korea Anal and Colorectal Cancer Market Forecast
      • 10.3.4 Southeast Asia Anal and Colorectal Cancer Market Forecast
      • 10.3.5 India Anal and Colorectal Cancer Market Forecast
      • 10.3.6 Australia Anal and Colorectal Cancer Market Forecast
    • 10.4 Europe Anal and Colorectal Cancer Forecast by Country (2025-2030)
      • 10.4.1 Germany Anal and Colorectal Cancer Market Forecast
      • 10.4.2 France Anal and Colorectal Cancer Market Forecast
      • 10.4.3 UK Anal and Colorectal Cancer Market Forecast
      • 10.4.4 Italy Anal and Colorectal Cancer Market Forecast
      • 10.4.5 Russia Anal and Colorectal Cancer Market Forecast
    • 10.5 Middle East & Africa Anal and Colorectal Cancer Forecast by Region (2025-2030)
      • 10.5.1 Egypt Anal and Colorectal Cancer Market Forecast
      • 10.5.2 South Africa Anal and Colorectal Cancer Market Forecast
      • 10.5.3 Israel Anal and Colorectal Cancer Market Forecast
      • 10.5.4 Turkey Anal and Colorectal Cancer Market Forecast
      • 10.5.5 GCC Countries Anal and Colorectal Cancer Market Forecast
    • 10.6 Global Anal and Colorectal Cancer Forecast by Type (2025-2030)
    • 10.7 Global Anal and Colorectal Cancer Forecast by Application (2025-2030)
  • 11 Key Players Analysis

    • 11.1 Abbott Diagnostics
      • 11.1.1 Abbott Diagnostics Company Information
      • 11.1.2 Abbott Diagnostics Anal and Colorectal Cancer Product Offered
      • 11.1.3 Abbott Diagnostics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.1.4 Abbott Diagnostics Main Business Overview
      • 11.1.5 Abbott Diagnostics Latest Developments
    • 11.2 Advaxis
      • 11.2.1 Advaxis Company Information
      • 11.2.2 Advaxis Anal and Colorectal Cancer Product Offered
      • 11.2.3 Advaxis Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.2.4 Advaxis Main Business Overview
      • 11.2.5 Advaxis Latest Developments
    • 11.3 Abbott
      • 11.3.1 Abbott Company Information
      • 11.3.2 Abbott Anal and Colorectal Cancer Product Offered
      • 11.3.3 Abbott Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.3.4 Abbott Main Business Overview
      • 11.3.5 Abbott Latest Developments
    • 11.4 Amgen
      • 11.4.1 Amgen Company Information
      • 11.4.2 Amgen Anal and Colorectal Cancer Product Offered
      • 11.4.3 Amgen Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.4.4 Amgen Main Business Overview
      • 11.4.5 Amgen Latest Developments
    • 11.5 Atara Biotherapeutics
      • 11.5.1 Atara Biotherapeutics Company Information
      • 11.5.2 Atara Biotherapeutics Anal and Colorectal Cancer Product Offered
      • 11.5.3 Atara Biotherapeutics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.5.4 Atara Biotherapeutics Main Business Overview
      • 11.5.5 Atara Biotherapeutics Latest Developments
    • 11.6 Bayer
      • 11.6.1 Bayer Company Information
      • 11.6.2 Bayer Anal and Colorectal Cancer Product Offered
      • 11.6.3 Bayer Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.6.4 Bayer Main Business Overview
      • 11.6.5 Bayer Latest Developments
    • 11.7 Metabiomics
      • 11.7.1 Metabiomics Company Information
      • 11.7.2 Metabiomics Anal and Colorectal Cancer Product Offered
      • 11.7.3 Metabiomics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.7.4 Metabiomics Main Business Overview
      • 11.7.5 Metabiomics Latest Developments
    • 11.8 Beckman Coulter
      • 11.8.1 Beckman Coulter Company Information
      • 11.8.2 Beckman Coulter Anal and Colorectal Cancer Product Offered
      • 11.8.3 Beckman Coulter Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.8.4 Beckman Coulter Main Business Overview
      • 11.8.5 Beckman Coulter Latest Developments
    • 11.9 BeiGene
      • 11.9.1 BeiGene Company Information
      • 11.9.2 BeiGene Anal and Colorectal Cancer Product Offered
      • 11.9.3 BeiGene Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.9.4 BeiGene Main Business Overview
      • 11.9.5 BeiGene Latest Developments
    • 11.10 Boehringer Ingelheim
      • 11.10.1 Boehringer Ingelheim Company Information
      • 11.10.2 Boehringer Ingelheim Anal and Colorectal Cancer Product Offered
      • 11.10.3 Boehringer Ingelheim Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.10.4 Boehringer Ingelheim Main Business Overview
      • 11.10.5 Boehringer Ingelheim Latest Developments
    • 11.11 Clinical Genomics
      • 11.11.1 Clinical Genomics Company Information
      • 11.11.2 Clinical Genomics Anal and Colorectal Cancer Product Offered
      • 11.11.3 Clinical Genomics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.11.4 Clinical Genomics Main Business Overview
      • 11.11.5 Clinical Genomics Latest Developments
    • 11.12 EDP Biotech
      • 11.12.1 EDP Biotech Company Information
      • 11.12.2 EDP Biotech Anal and Colorectal Cancer Product Offered
      • 11.12.3 EDP Biotech Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.12.4 EDP Biotech Main Business Overview
      • 11.12.5 EDP Biotech Latest Developments
    • 11.13 Eli Lilly
      • 11.13.1 Eli Lilly Company Information
      • 11.13.2 Eli Lilly Anal and Colorectal Cancer Product Offered
      • 11.13.3 Eli Lilly Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.13.4 Eli Lilly Main Business Overview
      • 11.13.5 Eli Lilly Latest Developments
    • 11.14 Epigenomics
      • 11.14.1 Epigenomics Company Information
      • 11.14.2 Epigenomics Anal and Colorectal Cancer Product Offered
      • 11.14.3 Epigenomics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.14.4 Epigenomics Main Business Overview
      • 11.14.5 Epigenomics Latest Developments
    • 11.15 Exact Sciences
      • 11.15.1 Exact Sciences Company Information
      • 11.15.2 Exact Sciences Anal and Colorectal Cancer Product Offered
      • 11.15.3 Exact Sciences Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.15.4 Exact Sciences Main Business Overview
      • 11.15.5 Exact Sciences Latest Developments
    • 11.16 Genomictree
      • 11.16.1 Genomictree Company Information
      • 11.16.2 Genomictree Anal and Colorectal Cancer Product Offered
      • 11.16.3 Genomictree Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.16.4 Genomictree Main Business Overview
      • 11.16.5 Genomictree Latest Developments
    • 11.17 Immunovaccine
      • 11.17.1 Immunovaccine Company Information
      • 11.17.2 Immunovaccine Anal and Colorectal Cancer Product Offered
      • 11.17.3 Immunovaccine Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.17.4 Immunovaccine Main Business Overview
      • 11.17.5 Immunovaccine Latest Developments
    • 11.18 ISA Pharmaceuticals
      • 11.18.1 ISA Pharmaceuticals Company Information
      • 11.18.2 ISA Pharmaceuticals Anal and Colorectal Cancer Product Offered
      • 11.18.3 ISA Pharmaceuticals Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.18.4 ISA Pharmaceuticals Main Business Overview
      • 11.18.5 ISA Pharmaceuticals Latest Developments
    • 11.19 Merck
      • 11.19.1 Merck Company Information
      • 11.19.2 Merck Anal and Colorectal Cancer Product Offered
      • 11.19.3 Merck Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2019-2024)
      • 11.19.4 Merck Main Business Overview
      • 11.19.5 Merck Latest Developments
  • 12 Research Findings and Conclusion

List of Tables Table 1. Anal and Colorectal Cancer Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions) Table 2. Major Players of Surgery Table 3. Major Players of Radiation therapy Table 4. Major Players of Colorectal cancer chemotherapy Table 5. Major Players of Targeted therapy Table 6. Major Players of Immunotherapy Table 7. Anal and Colorectal Cancer Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions) Table 8. Global Anal and Colorectal Cancer Market Size by Type (2019-2024) & ($ Millions) Table 9. Global Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024) Table 10. Anal and Colorectal Cancer Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions) Table 11. Global Anal and Colorectal Cancer Market Size by Application (2019-2024) & ($ Millions) Table 12. Global Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024) Table 13. Global Anal and Colorectal Cancer Revenue by Players (2019-2024) & ($ Millions) Table 14. Global Anal and Colorectal Cancer Revenue Market Share by Player (2019-2024) Table 15. Anal and Colorectal Cancer Key Players Head office and Products Offered Table 16. Anal and Colorectal Cancer Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) Table 17. New Products and Potential Entrants Table 18. Mergers & Acquisitions, Expansion Table 19. Global Anal and Colorectal Cancer Market Size by Regions 2019-2024 & ($ Millions) Table 20. Global Anal and Colorectal Cancer Market Size Market Share by Regions (2019-2024) Table 21. Global Anal and Colorectal Cancer Revenue by Country/Region (2019-2024) & ($ millions) Table 22. Global Anal and Colorectal Cancer Revenue Market Share by Country/Region (2019-2024) Table 23. Americas Anal and Colorectal Cancer Market Size by Country (2019-2024) & ($ Millions) Table 24. Americas Anal and Colorectal Cancer Market Size Market Share by Country (2019-2024) Table 25. Americas Anal and Colorectal Cancer Market Size by Type (2019-2024) & ($ Millions) Table 26. Americas Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024) Table 27. Americas Anal and Colorectal Cancer Market Size by Application (2019-2024) & ($ Millions) Table 28. Americas Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024) Table 29. APAC Anal and Colorectal Cancer Market Size by Region (2019-2024) & ($ Millions) Table 30. APAC Anal and Colorectal Cancer Market Size Market Share by Region (2019-2024) Table 31. APAC Anal and Colorectal Cancer Market Size by Type (2019-2024) & ($ Millions) Table 32. APAC Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024) Table 33. APAC Anal and Colorectal Cancer Market Size by Application (2019-2024) & ($ Millions) Table 34. APAC Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024) Table 35. Europe Anal and Colorectal Cancer Market Size by Country (2019-2024) & ($ Millions) Table 36. Europe Anal and Colorectal Cancer Market Size Market Share by Country (2019-2024) Table 37. Europe Anal and Colorectal Cancer Market Size by Type (2019-2024) & ($ Millions) Table 38. Europe Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024) Table 39. Europe Anal and Colorectal Cancer Market Size by Application (2019-2024) & ($ Millions) Table 40. Europe Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024) Table 41. Middle East & Africa Anal and Colorectal Cancer Market Size by Region (2019-2024) & ($ Millions) Table 42. Middle East & Africa Anal and Colorectal Cancer Market Size Market Share by Region (2019-2024) Table 43. Middle East & Africa Anal and Colorectal Cancer Market Size by Type (2019-2024) & ($ Millions) Table 44. Middle East & Africa Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024) Table 45. Middle East & Africa Anal and Colorectal Cancer Market Size by Application (2019-2024) & ($ Millions) Table 46. Middle East & Africa Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024) Table 47. Key Market Drivers & Growth Opportunities of Anal and Colorectal Cancer Table 48. Key Market Challenges & Risks of Anal and Colorectal Cancer Table 49. Key Industry Trends of Anal and Colorectal Cancer Table 50. Global Anal and Colorectal Cancer Market Size Forecast by Regions (2025-2030) & ($ Millions) Table 51. Global Anal and Colorectal Cancer Market Size Market Share Forecast by Regions (2025-2030) Table 52. Global Anal and Colorectal Cancer Market Size Forecast by Type (2025-2030) & ($ Millions) Table 53. Global Anal and Colorectal Cancer Market Size Forecast by Application (2025-2030) & ($ Millions) Table 54. Abbott Diagnostics Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 55. Abbott Diagnostics Anal and Colorectal Cancer Product Offered Table 56. Abbott Diagnostics Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 57. Abbott Diagnostics Main Business Table 58. Abbott Diagnostics Latest Developments Table 59. Advaxis Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 60. Advaxis Anal and Colorectal Cancer Product Offered Table 61. Advaxis Main Business Table 62. Advaxis Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 63. Advaxis Latest Developments Table 64. Abbott Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 65. Abbott Anal and Colorectal Cancer Product Offered Table 66. Abbott Main Business Table 67. Abbott Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 68. Abbott Latest Developments Table 69. Amgen Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 70. Amgen Anal and Colorectal Cancer Product Offered Table 71. Amgen Main Business Table 72. Amgen Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 73. Amgen Latest Developments Table 74. Atara Biotherapeutics Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 75. Atara Biotherapeutics Anal and Colorectal Cancer Product Offered Table 76. Atara Biotherapeutics Main Business Table 77. Atara Biotherapeutics Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 78. Atara Biotherapeutics Latest Developments Table 79. Bayer Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 80. Bayer Anal and Colorectal Cancer Product Offered Table 81. Bayer Main Business Table 82. Bayer Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 83. Bayer Latest Developments Table 84. Metabiomics Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 85. Metabiomics Anal and Colorectal Cancer Product Offered Table 86. Metabiomics Main Business Table 87. Metabiomics Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 88. Metabiomics Latest Developments Table 89. Beckman Coulter Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 90. Beckman Coulter Anal and Colorectal Cancer Product Offered Table 91. Beckman Coulter Main Business Table 92. Beckman Coulter Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 93. Beckman Coulter Latest Developments Table 94. BeiGene Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 95. BeiGene Anal and Colorectal Cancer Product Offered Table 96. BeiGene Main Business Table 97. BeiGene Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 98. BeiGene Latest Developments Table 99. Boehringer Ingelheim Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 100. Boehringer Ingelheim Anal and Colorectal Cancer Product Offered Table 101. Boehringer Ingelheim Main Business Table 102. Boehringer Ingelheim Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 103. Boehringer Ingelheim Latest Developments Table 104. Clinical Genomics Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 105. Clinical Genomics Anal and Colorectal Cancer Product Offered Table 106. Clinical Genomics Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 107. Clinical Genomics Main Business Table 108. Clinical Genomics Latest Developments Table 109. EDP Biotech Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 110. EDP Biotech Anal and Colorectal Cancer Product Offered Table 111. EDP Biotech Main Business Table 112. EDP Biotech Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 113. EDP Biotech Latest Developments Table 114. Eli Lilly Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 115. Eli Lilly Anal and Colorectal Cancer Product Offered Table 116. Eli Lilly Main Business Table 117. Eli Lilly Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 118. Eli Lilly Latest Developments Table 119. Epigenomics Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 120. Epigenomics Anal and Colorectal Cancer Product Offered Table 121. Epigenomics Main Business Table 122. Epigenomics Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 123. Epigenomics Latest Developments Table 124. Exact Sciences Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 125. Exact Sciences Anal and Colorectal Cancer Product Offered Table 126. Exact Sciences Main Business Table 127. Exact Sciences Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 128. Exact Sciences Latest Developments Table 129. Genomictree Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 130. Genomictree Anal and Colorectal Cancer Product Offered Table 131. Genomictree Main Business Table 132. Genomictree Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 133. Genomictree Latest Developments Table 134. Immunovaccine Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 135. Immunovaccine Anal and Colorectal Cancer Product Offered Table 136. Immunovaccine Main Business Table 137. Immunovaccine Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 138. Immunovaccine Latest Developments Table 139. ISA Pharmaceuticals Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 140. ISA Pharmaceuticals Anal and Colorectal Cancer Product Offered Table 141. ISA Pharmaceuticals Main Business Table 142. ISA Pharmaceuticals Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 143. ISA Pharmaceuticals Latest Developments Table 144. Merck Details, Company Type, Anal and Colorectal Cancer Area Served and Its Competitors Table 145. Merck Anal and Colorectal Cancer Product Offered Table 146. Merck Main Business Table 147. Merck Anal and Colorectal Cancer Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 148. Merck Latest Developments List of Figures Figure 1. Anal and Colorectal Cancer Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Anal and Colorectal Cancer Market Size Growth Rate 2019-2030 ($ Millions) Figure 6. Anal and Colorectal Cancer Sales by Geographic Region (2019, 2023 & 2030) & ($ millions) Figure 7. Anal and Colorectal Cancer Sales Market Share by Country/Region (2023) Figure 8. Anal and Colorectal Cancer Sales Market Share by Country/Region (2019, 2023 & 2030) Figure 9. Global Anal and Colorectal Cancer Market Size Market Share by Type in 2023 Figure 10. Anal and Colorectal Cancer in Hospitals Figure 11. Global Anal and Colorectal Cancer Market: Hospitals (2019-2024) & ($ Millions) Figure 12. Anal and Colorectal Cancer in Ambulatory surgery centers Figure 13. Global Anal and Colorectal Cancer Market: Ambulatory surgery centers (2019-2024) & ($ Millions) Figure 14. Anal and Colorectal Cancer in Cancer research centers Figure 15. Global Anal and Colorectal Cancer Market: Cancer research centers (2019-2024) & ($ Millions) Figure 16. Global Anal and Colorectal Cancer Market Size Market Share by Application in 2023 Figure 17. Global Anal and Colorectal Cancer Revenue Market Share by Player in 2023 Figure 18. Global Anal and Colorectal Cancer Market Size Market Share by Regions (2019-2024) Figure 19. Americas Anal and Colorectal Cancer Market Size 2019-2024 ($ Millions) Figure 20. APAC Anal and Colorectal Cancer Market Size 2019-2024 ($ Millions) Figure 21. Europe Anal and Colorectal Cancer Market Size 2019-2024 ($ Millions) Figure 22. Middle East & Africa Anal and Colorectal Cancer Market Size 2019-2024 ($ Millions) Figure 23. Americas Anal and Colorectal Cancer Value Market Share by Country in 2023 Figure 24. United States Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 25. Canada Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 26. Mexico Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 27. Brazil Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 28. APAC Anal and Colorectal Cancer Market Size Market Share by Region in 2023 Figure 29. APAC Anal and Colorectal Cancer Market Size Market Share by Type in 2023 Figure 30. APAC Anal and Colorectal Cancer Market Size Market Share by Application in 2023 Figure 31. China Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 32. Japan Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 33. Korea Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 34. Southeast Asia Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 35. India Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 36. Australia Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 37. Europe Anal and Colorectal Cancer Market Size Market Share by Country in 2023 Figure 38. Europe Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024) Figure 39. Europe Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024) Figure 40. Germany Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 41. France Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 42. UK Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 43. Italy Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 44. Russia Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 45. Middle East & Africa Anal and Colorectal Cancer Market Size Market Share by Region (2019-2024) Figure 46. Middle East & Africa Anal and Colorectal Cancer Market Size Market Share by Type (2019-2024) Figure 47. Middle East & Africa Anal and Colorectal Cancer Market Size Market Share by Application (2019-2024) Figure 48. Egypt Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 49. South Africa Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 50. Israel Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 51. Turkey Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 52. GCC Country Anal and Colorectal Cancer Market Size Growth 2019-2024 ($ Millions) Figure 53. Americas Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 54. APAC Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 55. Europe Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 56. Middle East & Africa Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 57. United States Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 58. Canada Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 59. Mexico Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 60. Brazil Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 61. China Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 62. Japan Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 63. Korea Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 64. Southeast Asia Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 65. India Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 66. Australia Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 67. Germany Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 68. France Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 69. UK Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 70. Italy Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 71. Russia Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 72. Spain Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 73. Egypt Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 74. South Africa Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 75. Israel Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 76. Turkey Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 77. GCC Countries Anal and Colorectal Cancer Market Size 2025-2030 ($ Millions) Figure 78. Global Anal and Colorectal Cancer Market Size Market Share Forecast by Type (2025-2030) Figure 79. Global Anal and Colorectal Cancer Market Size Market Share Forecast by Application (2025-2030)

価格:USD 3,660
543,218もしくは部分購入
適用レート
1 USD = 148.42
※稀に出版元により価格が改定されている場合がございます。
contact
© 2023 ShareFair Inc.